- Management team will host R&D day on Thursday, September 15, from 10am ET in New York City with Key Opinion Leader (KOL) participation
- Pipeline and business update, translational and clinical data on eblasakimab in development for moderate-to-severe atopic dermatitis (AD) and other topics related to the AD landscape to be discussed with a live webcast option
MENLO PARK, Calif. and SINGAPORE, Aug. 22, 2022 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will be hosting a R&D Day on Thursday, September 15, 2022, from 10:00am to 1:30pm ET at the St. Regis Hotel in New York, NY.
The event will include presentations from management as well as Key Opinion Leaders (KOLs) in dermatology, Peter A. Lio, MD of Northwestern University Feinberg School of Medicine, and Shawn Kwatra, MD of Johns Hopkins University, who will discuss the emerging unmet needs, therapeutic landscape and molecular mechanisms underlying AD.
ASLAN’s leadership team including Carl Firth PhD (Founder and CEO), Stephen Doyle (Chief Business Officer), Alex Kaoukhov MD (Chief Medical Officer), and other members of the senior R&D management team will discuss the pipeline portfolio led by eblasakimab, a potential novel, first-in-class monoclonal antibody that targets the IL-13 receptor α1 subunit (IL-13Rα1) being developed for the treatment of moderate-to-severe AD.
The event will provide a comprehensive update on the eblasakimab development program, including:
- Translational data on eblasakimab’s unique mechanism of action
- Clinical data from the Phase 1b proof-of-concept study of eblasakimab
- Overview of eblasakimab’s development strategy and path to market
- Update on the latest in AD research
Formal presentations will be followed by a KOL panel discussion.
To attend the event in person or virtually, please click here for registration. For in-person attendance, please register in advance as space is limited. A replay of the event and presentation materials will be available on the Investor Relations section of ASLAN’s website at https://ir.aslanpharma.com/
About eblasakimab
Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for atopic dermatitis patients. In September 2021, ASLAN announced positive results from the Phase 1b multiple-ascending-dose study that established proof-of-concept of eblasakimab and supported its potential as a novel treatment for AD. In early 2022, ASLAN initiated the TREK-AD Phase 2b trial to evaluate the safety and efficacy of eblasakimab in moderate-to-severe AD patients.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat (also known as ASLAN003), a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.
Forward looking statements
This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and/or its affiliates (the "Company"). These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy and clinical development plans; the Company’s plans to develop and commercialize eblasakimab and farudodstat; the safety and efficacy of eblasakimab and farudodstat; the Company’s plans and expected timing with respect to clinical trials, clinical trial enrolment and clinical trial results for eblasakimab and farudodstat; the potential of eblasakimab as a first-in-class treatment for atopic dermatitis; and of farudodstat as a treatment for autoimmune disease. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations, or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic or the ongoing conflict between Ukraine and Russia on the Company’s business and the global economy; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s US Securities and Exchange Commission filings and reports (Commission File No. 001- 38475), including the Company’s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on March 25, 2022. All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections, and other forward-looking statements. Estimates, projections, and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement.
Media and IR contacts
| Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email:ASLAN@spurwingcomms.com |
Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email:arr@lifesciadvisors.com |
